Diagnostic Consultative Centre Ascendent OOD
Verified site
Sofia, Bulgaria
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
Esomeprazole is a medication commonly used to reduce stomach acid and treat conditions such as heartburn, gastroesophageal reflux disease, and ulcers. In this study the drug is given either as a liquid form called Esomeprazole‑Syrup 40 mg or as a tablet marketed under the name Nexium 40 mg.
The purpose of the study is to compare the bioavailability of the liquid formulation with that of the tablet, meaning how much of the medicine reaches the bloodstream after a single dose. The researchers will measure the total exposure of the drug in the blood, known as AUC, and the highest level reached, called Cmax, as well as the time it takes to reach that highest level.
Healthy volunteers will take one dose of the liquid and one dose of the tablet on separate visits, with each visit performed after an overnight fast and after a standard meal, creating four different testing periods. The visits are spaced several days apart, and blood samples are collected after each dose to determine how the body absorbs the medication under the different conditions.
The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.
8 criteria
30 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Sofia, Bulgaria
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a liquid medicine taken by mouth that contains esomeprazole, a drug that lowers the amount of acid your stomach makes. In this study it is the new test product, and researchers are checking how well the body absorbs it when taken on an empty stomach and after a meal.
are the standard, market‑available pills that also contain esomeprazole. They have a special coating that protects the medicine from stomach acid until it reaches the intestine. In the trial they are used as the comparison product to see if the syrup works as well as these well‑known tablets.
This product is an oral solution (syrup) that delivers 40 mg of esomeprazole magnesium trihydrate in 10 mL and is taken by mouth. It contains a drug that is already approved and well‑studied in medical literature as a proton‑pump inhibitor. It is used to treat conditions caused by excess stomach acid, such as heartburn, gastro‑esophageal reflux disease, and ulcers. It works by blocking the stomach’s acid‑producing pump (the H⁺/K⁺‑ATPase), which lowers the amount of acid released, and it belongs to the class of proton‑pump inhibitors.
This product is a gastro‑resistant tablet that contains 40 mg of esomeprazole magnesium trihydrate and is swallowed whole. It is an approved medication with extensive documentation in the medical literature as a proton‑pump inhibitor. It is indicated for the same acid‑related conditions such as heartburn, gastro‑esophageal reflux disease, and ulcer disease. It reduces stomach acid by inhibiting the H⁺/K⁺‑ATPase pump in the stomach lining and is classified as a proton‑pump inhibitor.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.